Click Here for the Guidance
Published , updated
Their guidance aims to help clinicians manage patients who are currently on a medicine that requires monitoring during the COVID-19 pandemic.
The objective is to both protect patients from unnecessary health care visits and help preserve capacity in primary care.
Overall, they recommend that drug monitoring during the COVID-19 pandemic is prioritised for patients that will gain most benefit, i.e.:
- Those at risk of a serious adverse drug event that can be identified through monitoring
- People taking a Narrow Therapeutic Index drug during a phase when intensive monitoring is still required (e.g. upon initiation)
- Patients who have recently had an illness that may have impacted on how their drug works
Their advice is not intended as a definitive treatment strategy
They have provided advice on factors to consider when making monitoring decisions during COVID-19.
Our advice on individual medicines is below. We’ll also shortly be adding all our individual medicines advice as a word document for local adaptation.
Azathioprine, leflunomide, mercatopurine, and methotrexate
The above pages are captured in the following word file and can be used for local adaptation
Guidance on the management of drugs requiring monitoring during COVID-19
